ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The French contract pharmaceutical services firm Seqens has opened a 1,400 m2 research and development center in Devens, Massachusetts. The $5 million facility, located near Boston, is intended to accelerate the firm’s development of active pharmaceutical ingredients and excipients, including lipids used in the manufacture of mRNA vaccines for COVID-19. The center replaces a smaller lab in Devens. Employees will transfer to the new center, where Seqens expects to double the number of scientists by 2026. Asymchem, a Chinese contract pharmaceutical services firm, plans to open a research center in nearby Woburn in the first quarter of this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X